Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panacea Life Sciences HoldingsPLSH 26 Equity-to-Asset is 0.94 as of Sep. 2025. GuruFocus rates PLSH with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 97.22% on this metric.
The historical rank and industry rank for Panacea Life Sciences Holdings's Equity-to-Asset or its related term are showing as below:
PLSH'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.45 Med: -0.16 Max: 0.94
Current: 0.94
During the past 4 years, the highest Equity to Asset Ratio of Panacea Life Sciences Holdings was 0.94. The lowest was -1.45. And the median was -0.16.
PLSH's Equity-to-Asset is ranked better than 97.22% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs PLSH: 0.94
Panacea Life Sciences Holdings (OTCPK:PLSH) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Panacea Life Sciences Holdings Equity-to-Asset Related Terms
Panacea Life Sciences Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings Equity-to-Asset Chart
PLSH vs SKYI, IMCC, CBDY: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's Equity-to-Asset falls into.
Panacea Life Sciences Holdings Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (PLSH) has a Equity-to-Asset of 0.94 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Panacea Life Sciences Holdings and its competitors. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #28 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 2.8%.
Is Panacea Life Sciences Holdings' Equity-to-Asset too high?
Panacea Life Sciences Holdings' current Equity-to-Asset is 0.94. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Panacea Life Sciences Holdings' value of 0.94 is 54.1% above this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #28 out of 1006 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Panacea Life Sciences Holdings has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Panacea Life Sciences Holdings' Equity-to-Asset compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #28 out of 1006 companies for Equity-to-Asset. This places Panacea Life Sciences Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Panacea Life Sciences Holdings' value of 0.94 is 54.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current Equity-to-Asset of 0.94 is 54.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Panacea Life Sciences Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current Equity-to-Asset is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94 and 54.1% above the Drug Manufacturers industry median of 0.61. Panacea Life Sciences Holdings' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current Equity-to-Asset is 0.94 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Business Description
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
26GF Score
Get the complete analysis for PLSH
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
